Strategic partnerships ZeClinics has established collaboration with Almirall and participates in high-profile industry events (BIO International Convention, BIO 2022/2023), indicating openness to partnered R&D programs and potential co-development or sponsored project opportunities with large pharma and biotech firms.

High-throughput potential Recent launch of a zebrafish-based high-throughput platform for rapid target validation and drug screening creates a compelling value proposition for customers seeking fast in vivo readouts and scalable screening capabilities to de-risk early discovery.

In vivo capability Specialization in CRISPR genome editing and custom zebrafish disease models positions ZeClinics as a go-to CRO for target validation, safety and efficacy assessments, and translational in vivo studies for pharma, nutraceutical, and agrochemical clients.

Funding momentum Secured EIC Pathfinder grant of €1M for the EdiGenT project and ongoing strategic R&D initiatives signal financial backing and a track record of innovation, suggesting capacity to scale services or pursue joint grant-funded projects with clients.

Global reach & positioning Active participation in international events and a client base spanning pharmaceuticals, biotech, academia, and other sectors imply opportunities to expand into US/EU markets, leverage case studies, and pursue multi-region collaborations with mid-sized biotech firms.